In early preclinical work, DHODH inhibitors appear to be effective at inducing differentiation in AML cells in a non-mutation specific manner (Christian et al., 2019; ClinicalTrials.gov; Sykes et al., 2016). Here, DHODH is linked to acute myeloid leukemia.